In a phase 3 clinical trial, osimertinib significantly prolonged progression-free survival to 18.9 months as compared to 10.2 months for patients with untreated EGFR-mutated advanced NSCLC received gefitinib or erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.